Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Menadiol is a synthetic, water-soluble analog of vitamin K3 (menadione). It serves as a precursor to the active form of vitamin K, which acts as an essential cofactor for the enzyme gamma-glutamyl carboxylase (GGCX). This enzyme facilitates the posttranslational gamma-carboxylation of glutamic acid residues in various vitamin K-dependent proteins, including blood coagulation factors (II, VII, IX, and X) and bone-related proteins such as osteocalcin and matrix Gla protein (MGP). Due to its water solubility, menadiol is particularly indicated for individuals with fat malabsorption conditions, such as cystic fibrosis or biliary obstruction, who cannot absorb naturally occurring fat-soluble vitamin K. It has been evaluated in Phase 3 clinical trials for its ability to improve bone mineral density and markers of bone formation in patients with cystic fibrosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on menadiol.